WAVE Life Sciences Continues Development of Two Drug Therapies for Huntington’s
May 16, 2017 12:46 pm | Joana Fernandes, PhD
WAVE Life Sciences’ products WVE-120101 (SNP-1) and WVE-120102 (SNP-2) will enter clinical trials in mid-2017 as part of the effort to develop new treatments for patients with Huntington’s disease. “2017 will be an important year for WAVE as we transition our two lead candidates in Huntington’s disease … into clinical trials,” Paul Bolno, MD, and […]
The post WAVE Life Sciences Continues Development of Two Drug Therapies for Huntington’s appeared first on Huntington's Disease News.